| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790171 | Urologic Oncology: Seminars and Original Investigations | 2018 | 8 Pages |
Abstract
Therapeutic equivalence between AAFP 500Â mg daily and OAA 1000Â mg daily based on serum testosterone levels was confirmed in mCRPC patients. Both agents led to similar PSA-50 response rates. Abiraterone trough levels were similar between treatments. No new safety concerns were observed.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Cy A. M.D., Ph.D., Richard M.D., Robert M.D., Celestia S. M.D., Paul Ph.D., Bill Ph.D., Jillian M.S., Robert M.D.,